drugset / Trial / NCT00206401

Lantus in the Treatment of Type 1 Diabetes Children

NCT00206401 ↗

Phase 4 Completed 60 enrolled Baylor College of Medicine
RandomizedParallel-groupOpen-labelTreatment

Summary

In this study, we plan to examine the difference in effect on blood glucose control in patients who will be on either conventional insulin therapy (i.e. using NPH and Humalog twice daily, injected separately) or on intensive insulin management (IIM-several shots of short acting and Glargine insulin). Those on IIM will be mixing the insulin Glargine with the short-acting insulin analog prior to injecting. The Hemoglobin A1c (HbA1c) results will be used to monitor blood glucose control over a 6 month period. Twice during the course of the study, a continuous glucose monitoring system (CGMS-a device the size of a pager that records blood sugar readings every 5 minutes) will be used to record all the changes in the blood glucose levels occurring over a 72-hour period.

Timeline

Start
2004-11
Primary completion
—
Completion
2006-10

Outcome

Met primary endpoint

paper at poststudy was 6.7% +/- 1.3% vs 7.6% +/- 1% in the insulin glargine versus neutral protamine Hagedorn group, respectively. PMID 18299307 ↗

paper given twice daily seems significantly more effective than the standard therapy in newly diagnosed type 1 diabetes. PMID 18299307 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic — —
Subject neutral protamine Hagedorn Protein / enzyme biologic — —